Skip to main content
Clinical Trials/NCT05662046
NCT05662046
Completed
Not Applicable

Deformity of the Forefoot in Children With Unilateral Cerebral Palsy

University Hospital, Brest2 sites in 1 country52 target enrollmentJune 14, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Forefoot Adductus
Sponsor
University Hospital, Brest
Enrollment
52
Locations
2
Primary Endpoint
Measure of the forefoot deformity prevalence in plegia and non-plegia foot during gait in unilateral cerebral palsy children
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Midfoot and backfoot deformities are well described in children with Cerebral palsy. However, data regarding forefoot deformities in Cerebral palsy remain scarce in a population were foot deformities are the most frequent musculo-skeletal deformities.

Detailed Description

Foot deformities are the most frequent musculo-skeletal deformities in children with Cerebral palsy. Pain starts in the foot, especially during gait in Cerebral Palsy Children (GMFCS I and II) and induce gait limitations, balance disorders, wounds, aesthetic disorders and difficulties to support shoes. Metatarsus Adductus is the most common foot deformity in children with or without disorder, occuring on 1-2/1000 births. In 4 to 14% of the children, evolution is not favorable at 5 years. In that case, the diagnostic of Cerebral palsy have to be considered.

Registry
clinicaltrials.gov
Start Date
June 14, 2018
End Date
June 14, 2018
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Child who benefit a standardised clinical evaluation before a 3D Gait Analysis with forefoot deformity measure
  • Child age less than 18 years old
  • Child with left or right unilateral cerebral palsy
  • Walking child ( GMFCS score I, II or III)
  • In case of several 3D Gait Analysis for the child: the 3D gait analysis was chosen first before any local spasticity treatment with botulinic toxin injection or the 3D gait evaluation the more far from local spastica treatment with botulinic toxin injection was chosen in second .

Exclusion Criteria

  • Hemiplegia due to another etiology
  • History of lower limb or foot surgery before the clinical evaluation
  • Local spasticy treatment with botulinic toxin injection less than 3 months before the clinical evaluation
  • Participation refusal

Outcomes

Primary Outcomes

Measure of the forefoot deformity prevalence in plegia and non-plegia foot during gait in unilateral cerebral palsy children

Time Frame: 1 day

we report in our population the forefoot axis measured by the angle between the heel bisector and the axis between the second and third metatarsal.

Secondary Outcomes

  • functional factors associated with forefoot deformities on plegia side in walking children with unilateral Cerebral Palsy.(1 day)
  • Motricity factors associated with forefoot deformities on plegia side in walking children with unilateral Cerebral Palsy.(1 day)
  • Anthropometric factors (type of cerebral palsy)associated with forefoot deformities on plegia side in walking children with unilateral Cerebral Palsy.(1 day)
  • Anthropometric factors (age) associated with forefoot deformities on plegia side in walking children with unilateral Cerebral Palsy.(1 day)
  • Anthropometric factors (sexe) associated with forefoot deformities on plegia side in walking children with unilateral Cerebral Palsy.(1 day)
  • biomechanical osteoarticular factors associated with forefoot deformities on plegia side in walking children with unilateral Cerebral Palsy.(1 day)
  • Spasticity factors associated with forefoot deformities on plegia side in walking children with unilateral Cerebral Palsy.(1 day)

Study Sites (2)

Loading locations...

Similar Trials